<DOC>
	<DOCNO>NCT00807235</DOCNO>
	<brief_summary>To evaluate feasibility , safety tolerability aerosolize lucinactant deliver nasal continuous positive airway pressure ( nCPAP ) prevention respiratory distress syndrome ( RDS ) premature infant .</brief_summary>
	<brief_title>Feasibility Study Aerosolized Surfaxin Prevention Respiratory Distress Syndrome ( RDS ) Premature Infants</brief_title>
	<detailed_description>Use device early treatment RDS permit effective aerosolization exogenous surfactant also allow simultaneous delivery continuous positive airway pressure would permit delivery surfactant distal airway without intubation . This approach could reduce frequency severity adverse event relative endotracheal intubation surfactant administration via bolus .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Pulmonary Surfactants</mesh_term>
	<criteria>Gestational age 2832 complete week , inclusive Placement arterial line Successful initiation nCPAP Informed Consent Heart rate stabilize &gt; 100 bpm within 5 minute birth Five ( 5 ) minute Apgar score â‰¤ 3 Major congenital malformation ( ) diagnose antenatally note immediately birth Other disease ( ) condition potentially interfere cardiopulmonary function Mother prolong rupture membrane &gt; 2 week Known suspected chromosomal abnormality Need chest compression administration epinephrine , bicarbonate , fluid bolus delivery room Need mechanical ventilation within 30 minute birth</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Minutes</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Lucinactant</keyword>
	<keyword>Nasal continuous positive airway pressure ( nCPAP )</keyword>
	<keyword>Respiratory distress syndrome ( RDS )</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Premature</keyword>
</DOC>